Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The impact of CYP2C19 genotype on phenoconversion by concomitant medication

8 Jun 2023

Abstract excerpt

Introduction: Pharmacogenetics-informed drug prescribing is increasingly applied in clinical practice. Typically, drug metabolizing phenotypes are determined based on genetic test results, whereupon dosage or drugs are adjusted. Drug-drug-interactions (DDIs) caused by concomitant medication can however cause mismatches between predicted and observed phenotypes (phenoconversion). Here we investigated the impact of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Transport and Resistance Mechanisms
Share to Pharmacogenetics and Drug Metabolism
Share to Statistical Methods in Clinical Trials

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37361233
DOI: 10.3389/fphar.2023.1201906

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The impact of CYP2C19 genotype on phenoconversion by concomitant medicationPMID 37361233Read ↗

Phenoconversion Due to Drug-Drug Interactions in CYP2C19 Genotyped Healthy Volunteers.Semantic proximity Read ↗

Combination of CYP2C19 genotype with non-genetic factors evoking phenoconversion improves phenotype prediction.Semantic proximity Read ↗

CYP2C19 genotype-phenotype correlation: current insights and unanswered questionsSemantic proximity Read ↗

CYP2D6 pharmacogenetics and phenoconversion in personalized medicine.Semantic proximity Read ↗

Prediction of in vivo clearance and associated variability of CYP2C19 substrates by genotypes in populations utilizing a pharmacogenetics-based mechanistic model.Semantic proximity Read ↗

From genes to drugs: CYP2C19 and pharmacogenetics in clinical practiceSemantic proximity Read ↗

Meta-analysis of probability estimates of worldwide variation of CYP2D6 and CYP2C19.Semantic proximity Read ↗

CYP2C19 genotype determines enzyme activity and inducibility of S-mephenytoin hydroxylase.Semantic proximity Read ↗

Efavirenz-mediated induction of omeprazole metabolism is CYP2C19 genotype dependent.Semantic proximity Read ↗

Effect of CYP2D6 and CYP2C19 genotypes on atomoxetine serum levels -- a study based on therapeutic drug monitoring dataSemantic proximity Read ↗

Addressing phenoconversion: the Achilles' heel of personalized medicine.Semantic proximity Read ↗

Effect of CYP2D6 and CYP2C19 genotypes on atomoxetine serum levels: A study based on therapeutic drug monitoring data.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.